Phase 1 N=24 Drug-Drug Interaction Study Between Colchicine and Cyclosporine
Pharmacokinetics · Healthy
Primary: Maximum Plasma Concentration (Cmax) — 2,720.04; 8,817.48 pg/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=30 Drug-Drug Interaction Study of Colchicine and Theophylline
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 9.76; 9.79 µg/mL
Phase 1 N=24 Drug-Drug Interaction Study of Colchicine and Azithromycin
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 2,737.00; 3,051.76 pg/mL
Phase 1 N=53 Mycophenolate Mofetil 250 mg Capsules Under Fasting Conditions
Healthy
Primary: Cmax - Maximum Observed Concentration — 8.5858; 9.2170 µg/mL
Phase 1 N=24 Topiramate 25 mg Capsule Mixed With Applesauce Under Fasting Conditions
Healthy
Primary: Cmax - Maximum Observed Concentration — 630.45; 631.49 ng/mL
Phase 1 N=24 Topiramate 25 mg Capsules Under Fasting Conditions
Healthy
Primary: Cmax - Maximum Observed Concentration — 799.78; 810.40 ng/mL
Phase 1 N=18 Topiramate 25 mg Capsules Under Fed Conditions
Healthy
Primary: Cmax - Maximum Observed Concentration — 573.29; 550.55 ng/mL
Phase 1 N=24 Topiramate 25 mg Tablets Under Fed Conditions
Healthy
Primary: Cmax - Maximum Observed Concentration — 633.96; 700.79 ng/mL
Phase 1 N=30 Topiramate 25 mg Tablets Under Fasting Conditions
Healthy
Primary: Cmax - Maximum Observed Concentration — 830.39; 880.78 ng/mL
Phase 1 N=40 Study the Safety and Effectiveness of MK7009 in Hepatitis C Infected Patients (MK-7009-004)(COMPLETED)
Hepatitis C
Primary: Safety and Tolerability of MK7009 — 2; 3; 6; 4 Participants
Phase 1 N=18 EASI Access II --- Follow-up Study to the EASI Access Trial
Disaster Medicine · Difficult Intravenous Access · Dehydration
Primary: Number of Participants With Successfully Placed EASI Lines — 18 Participants
Phase 1 N=31 Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1)
Migraine Disorders
Primary: Safety and Tolerability of Single Doses of Rizatriptan in Pediatric Migraineurs — 0; 0; 0; 3 Participants
Phase 1 N=36 Comparison of One Morphine Sulfate Sustained-Release 200 mg Capsule With Two 100 mg KADIAN Capsules on Applesauce
Healthy
Primary: Maximum Plasma Morphine Concentration — 37.5; 38.0 ng/mL — p=<0.05
Phase 1 N=36 Comparison of One Morphine Sulfate Sustained-Release 200mg Capsule With Two 100 mg KADIAN Capsules Under Fed Conditions
Healthy
Primary: Mean Maximum Plasma Morphine Concentration — 37.3; 32.8 ng/mL
Phase 1 N=36 Comparison of One Morphine Sulfate Sustained-Release 200mg Capsule With Two 100 mg KADIAN Capsules Under Fasting Conditions
Healthy
Primary: Maximum Plasma Morphine Concentration — 42.8; 46.8 ng/mL